Select a community
MS
Find out more about the PatientsLikeMe
MS Community
Home > Community Treatment Reports > Carbatrol (carbamazepine) Treatment Report
What is Carbatrol?

Carbatrol® is a brand name for carbamazepine. It is used to treat partial and mixed seizure patterns, generalized tonic-clonic seizures and trigeminal neuralgia. Off label it is used to treat resistant schizophrenia, alcohol withdrawal, restless leg syndrome and post traumatic stress disorders.

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Other 4 0
Trigeminal neuralgia 3 1
Stiffness/Spasticity 2 1
Facial Nerve Pain 1 1
burning skin 1 0
Pain 1 0

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
0 0%
Mild
0 0%
None
2 100%

Dosages

  200 mg daily 300 mg daily 400 daily 400 mg daily 600 mg daily 1200 mg daily
  3 Number of Patients: 3 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 2 Number of Patients: 2 1 Number of Patients: 1  

Stop Reasons

Why Patients Stopped Taking Carbatrol (multiple reasons could be selected)
Reason # Patients Percentage of patients
Other
3 60% Other: 60%
Side effects too severe
2 40% Side effects too severe: 40%
Personal research
1 20% Personal research: 20%

See all 5 patients who’ve stopped taking Carbatrol

Currently Taking Carbatrol

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
1
0
0
2
2
2

Stopped Taking Carbatrol

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
1
0
0
0
3
1

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
2 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
0 0%
Not at all
2 100%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
1 50%
< $25
0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 21, 2009.